Willingness-to-Pay for a New Pharmaceutical: Is it Worth the Money? Whose Money?
During this OHE Lunchtime Seminar, Prof Peter Zweifel, University of Zurich, will discuss the findings from a discrete-choice experiment conducted in Germany to elicit the willingness to pay for modern insulin therapy using a long-acting insulin analogue rather than conventional insulin. Choice experiments such as this could pave the way for actually applying the cost-benefit standard to health care. For more details, see our earlier post.
The seminar will be held 12.00-2.00 PM, Friday, 16 July, at the OHE, 12 Whitehall, London. Space is limited at this seminar.
Posted in Health Technology Assessment, Pricing and Reimbursement | Tagged Events